Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction

X
Trial Profile

A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary) ; Dexamethasone; Enoxaparin sodium; Remdesivir
  • Indications COVID 2019 infections; COVID-19 respiratory infection
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Aug 2023 According to an Enlivex Therapeutics media release, data from this study were peer-reviewed published in Frontiers in Immunology.
    • 02 Aug 2023 Results presented in an Enlivex Therapeutics media release.
    • 03 Feb 2021 Results presented in an Enlivex Therapeutics Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top